BPA Biosante Pharmaceuticals

BioSante Pharmaceuticals, Inc. (Amex:BPA) today announced that Stephen M. Simes, the Company�s president and chief executive officer, will present a corporate and clinical overview of the Company at two upcoming biotech/specialty pharma and investor conferences. The first is at the Wall Street Reporter Small-Cap Discovery Conference on December 5, 2006 at 10:30 am EST at the Princeton Club in New York. The second is the New York Society of Securities Analysts (NYSSA) Biotech/Specialty Pharma Conference on December 12, 2006 at 11:40 am EST at the Society�s headquarters in New York. Live audio webcasts of BioSante�s presentations on December 5, and December 12, 2006 may be accessed at http://www.biosantepharma.com/investors/events.html and replays will be available at the same link for up to one year. About BioSante Pharmaceuticals, Inc. BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bioidentical estradiol and testosterone. BioSante's lead products include Bio-E-Gel� (transdermal estradiol gel) for the treatment of women with menopausal symptoms, and LibiGel� (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD). A Bio-E-Gel new drug application (NDA) was submitted to the FDA in the first quarter 2006. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion. The transdermal gel formulations used in the women's gel products are licensed by BioSante from Antares Pharma Inc. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, including avian flu and biodefense vaccines for toxins such as anthrax and ricin, and drug delivery systems. Additional information is available online at: www.biosantepharma.com. BioSante Pharmaceuticals, Inc. (Amex:BPA) today announced that Stephen M. Simes, the Company's president and chief executive officer, will present a corporate and clinical overview of the Company at two upcoming biotech/specialty pharma and investor conferences. The first is at the Wall Street Reporter Small-Cap Discovery Conference on December 5, 2006 at 10:30 am EST at the Princeton Club in New York. The second is the New York Society of Securities Analysts (NYSSA) Biotech/Specialty Pharma Conference on December 12, 2006 at 11:40 am EST at the Society's headquarters in New York. Live audio webcasts of BioSante's presentations on December 5, and December 12, 2006 may be accessed at http://www.biosantepharma.com/investors/events.html and replays will be available at the same link for up to one year. About BioSante Pharmaceuticals, Inc. BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bioidentical estradiol and testosterone. BioSante's lead products include Bio-E-Gel(R) (transdermal estradiol gel) for the treatment of women with menopausal symptoms, and LibiGel(R) (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD). A Bio-E-Gel new drug application (NDA) was submitted to the FDA in the first quarter 2006. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion. The transdermal gel formulations used in the women's gel products are licensed by BioSante from Antares Pharma Inc. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, including avian flu and biodefense vaccines for toxins such as anthrax and ricin, and drug delivery systems. Additional information is available online at: www.biosantepharma.com.